Logo image of ELAB

PMGC HOLDINGS INC (ELAB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ELAB - US73017P3001 - Common Stock

5.31 USD
0 (0%)
Last: 12/1/2025, 2:15:07 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ELAB. ELAB was compared to 36 industry peers in the Personal Care Products industry. While ELAB has a great health rating, there are worries on its profitability. ELAB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ELAB had negative earnings in the past year.
ELAB had a negative operating cash flow in the past year.
In the past 5 years ELAB always reported negative net income.
ELAB had a negative operating cash flow in each of the past 5 years.
ELAB Yearly Net Income VS EBIT VS OCF VS FCFELAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

ELAB has a worse Return On Assets (-69.45%) than 91.67% of its industry peers.
ELAB has a worse Return On Equity (-93.79%) than 80.56% of its industry peers.
Industry RankSector Rank
ROA -69.45%
ROE -93.79%
ROIC N/A
ROA(3y)-98.18%
ROA(5y)N/A
ROE(3y)-148.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELAB Yearly ROA, ROE, ROICELAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

Looking at the Gross Margin, with a value of 99.34%, ELAB belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ELAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELAB Yearly Profit, Operating, Gross MarginsELAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200

More info and screens

7

2. Health

2.1 Basic Checks

ELAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ELAB has more shares outstanding than it did 1 year ago.
ELAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ELAB Yearly Shares OutstandingELAB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K
ELAB Yearly Total Debt VS Total AssetsELAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

ELAB has an Altman-Z score of -1.39. This is a bad value and indicates that ELAB is not financially healthy and even has some risk of bankruptcy.
ELAB has a worse Altman-Z score (-1.39) than 83.33% of its industry peers.
There is no outstanding debt for ELAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.39
ROIC/WACCN/A
WACC8.66%
ELAB Yearly LT Debt VS Equity VS FCFELAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

2.3 Liquidity

A Current Ratio of 3.36 indicates that ELAB has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.36, ELAB belongs to the top of the industry, outperforming 80.56% of the companies in the same industry.
ELAB has a Quick Ratio of 3.36. This indicates that ELAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.36, ELAB belongs to the top of the industry, outperforming 86.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 3.36
ELAB Yearly Current Assets VS Current LiabilitesELAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.83% over the past year.
ELAB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -33.34%.
EPS 1Y (TTM)7.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.3%
Revenue 1Y (TTM)-33.34%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELAB Yearly Revenue VS EstimatesELAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 500K 1M 1.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELAB Price Earnings VS Forward Price EarningsELAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELAB Per share dataELAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PMGC HOLDINGS INC

NASDAQ:ELAB (12/1/2025, 2:15:07 PM)

5.31

0 (0%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)11-14 2025-11-14
Earnings (Next)03-23 2026-03-23
Inst Owners2.71%
Inst Owner Change-97.12%
Ins Owners0.08%
Ins Owner Change0%
Market Cap3.93M
Revenue(TTM)1.14M
Net Income(TTM)-6.25M
AnalystsN/A
Price TargetN/A
Short Float %28.72%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.44
P/FCF N/A
P/OCF N/A
P/B 0.59
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-320.19
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-6.17
FCFYN/A
OCF(TTM)-6.16
OCFYN/A
SpS1.54
BVpS9
TBVpS5.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.45%
ROE -93.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.34%
FCFM N/A
ROA(3y)-98.18%
ROA(5y)N/A
ROE(3y)-148.34%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.73%
Cap/Sales 0.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 3.36
Altman-Z -1.39
F-Score4
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-33.34%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-180.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-186.59%
OCF growth 3YN/A
OCF growth 5YN/A

PMGC HOLDINGS INC / ELAB FAQ

Can you provide the ChartMill fundamental rating for PMGC HOLDINGS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ELAB.


Can you provide the valuation status for PMGC HOLDINGS INC?

ChartMill assigns a valuation rating of 0 / 10 to PMGC HOLDINGS INC (ELAB). This can be considered as Overvalued.


How profitable is PMGC HOLDINGS INC (ELAB) stock?

PMGC HOLDINGS INC (ELAB) has a profitability rating of 1 / 10.